|Articles|December 29, 2021

Rheumatology Network's Highlights of 2021

Author(s)Lana Pine

A year in review of Rheumatology Network's top stories.

Related Content

FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis

FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis

ByVictoria Johnson

January 14th 2026

Susan Manzi, MD, MPH Credit: Allegheny Health Network

Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus Erythematosus

ByChelsie Derman

January 14th 2026

The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MD

The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MD

ByRosalind Ramsey-Goldman, MD

January 13th 2026

Tirzepatide Boosts Izekizumab Efficacy for PsA and Obesity Disease Control

Tirzepatide Boosts Izekizumab Efficacy for PsA and Obesity Disease Control

ByVictoria Johnson

January 12th 2026

5 Rheumatology Headlines You Missed in December 2025

5 Rheumatology Headlines You Missed in December 2025

ByVictoria Johnson

January 9th 2026